William D Tap1,2, Andrew J Wagner3, Patrick Schöffski4, Javier Martin-Broto5, Anders Krarup-Hansen6, Kristen N Ganjoo7, Chueh-Chuan Yen8,9, Albiruni R Abdul Razak10, Alexander Spira11, Akira Kawai12, Axel Le Cesne13, Brian A Van Tine14, Yoichi Naito15, Se Hoon Park16, Alexander Fedenko17, Zsuzsanna Pápai18, Victoria Soldatenkova19, Ashwin Shahir20, Gary Mo19, Jennifer Wright19, Robin L Jones21. 1. Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York. 2. Department of Medicine, Weill Cornell Medical College, New York, New York. 3. Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts. 4. University Hospitals Leuven, Department of General Medical Oncology, Leuven Cancer Institute, Leuven, Belgium. 5. Medical Oncology Department in University Hospital Virgen del Rocio and Institute of Biomedicine of Sevilla (IBIS) (HUVR, CSIC, University of Sevilla), Sevilla, Spain. 6. University of Copenhagen, Copenhagen, Denmark. 7. Stanford University, Stanford, California. 8. Division of Medical Oncology, Center for Immuno-oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan. 9. National Yang-Ming University School of Medicine, Taipei, Taiwan. 10. Princess Margaret Cancer Center, Toronto, Ontario, Canada. 11. Virginia Cancer Specialists, Fairfax. 12. National Cancer Center Hospital, Tokyo, Japan. 13. Institut Gustave Roussy, Villejuif, France. 14. Department of Internal Medicine, Washington University in St Louis School of Medicine, St Louis, Missouri. 15. National Cancer Center Hospital East, Kashiwa, Japan. 16. Sungkyunkwan University Samsung Medical Center, Seoul, Republic of Korea. 17. Blokhin Cancer Research Center, Moscow, Russian Federation. 18. Magyar Honvedseg Eu Kp, Budapest, Hungary. 19. Eli Lilly and Company, Indianapolis, Indiana. 20. Eli Lilly and Company, Windlesham, United Kingdom. 21. Sarcoma Unit, Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, United Kingdom.
Abstract
Importance: Patients with advanced soft tissue sarcoma (STS) have a median overall survival of less than 2 years. In a phase 2 study, an overall survival benefit in this population was observed with the addition of olaratumab to doxorubicin over doxorubicin alone. Objective: To determine the efficacy of doxorubicin plus olaratumab in patients with advanced/metastatic STS. Design, Setting, and Participants: ANNOUNCE was a confirmatory, phase 3, double-blind, randomized trial conducted at 110 sites in 25 countries from September 2015 to December 2018; the final date of follow-up was December 5, 2018. Eligible patients were anthracycline-naive adults with unresectable locally advanced or metastatic STS, an Eastern Cooperative Oncology Group performance status of 0 to 1, and cardiac ejection fraction of 50% or greater. Interventions: Patients were randomized 1:1 to receive doxorubicin, 75 mg/m2 (day 1), combined with olaratumab (n = 258), 20 mg/kg in cycle 1 and 15 mg/kg in subsequent cycles, or placebo (n = 251) on days 1 and 8 for up to 8 21-day cycles, followed by olaratumab/placebo monotherapy. Main Outcomes and Measures: Dual primary end points were overall survival with doxorubicin plus olaratumab vs doxorubicin plus placebo in total STS and leiomyosarcoma (LMS) populations. Results: Among the 509 patients randomized (mean age, 56.9 years; 58.2% women; 46.0% with LMS), all were included in the primary analysis and had a median length of follow-up of 31 months. No statistically significant difference in overall survival was observed between the doxorubicin plus olaratumab group vs the doxorubicin plus placebo group in either population (total STS: hazard ratio, 1.05 [95% CI, 0.84-1.30], P = .69, median overall survival, 20.4 months vs 19.7 months; LMS: hazard ratio, 0.95 [95% CI, 0.69-1.31], P = .76, median overall survival, 21.6 months vs 21.9 months). Adverse events of grade 3 or greater reported in 15% or more of total patients with STS were neutropenia (46.3% vs 49.0%), leukopenia (23.3% vs 23.7%), and febrile neutropenia (17.5% vs 16.5%). Conclusions and Relevance: In this phase 3 clinical trial of patients with advanced STS, treatment withdoxorubicin plus olaratumab vs doxorubicin plus placebo resulted in no significant difference in overall survival. The findings did not confirm the overall survival benefit observed in the phase 2 trial. Trial Registration: ClinicalTrials.gov Identifier: NCT02451943.
RCT Entities:
Importance: Patients with advanced soft tissue sarcoma (STS) have a median overall survival of less than 2 years. In a phase 2 study, an overall survival benefit in this population was observed with the addition of olaratumab to doxorubicin over doxorubicin alone. Objective: To determine the efficacy of doxorubicin plus olaratumab in patients with advanced/metastatic STS. Design, Setting, and Participants: ANNOUNCE was a confirmatory, phase 3, double-blind, randomized trial conducted at 110 sites in 25 countries from September 2015 to December 2018; the final date of follow-up was December 5, 2018. Eligible patients were anthracycline-naive adults with unresectable locally advanced or metastatic STS, an Eastern Cooperative Oncology Group performance status of 0 to 1, and cardiac ejection fraction of 50% or greater. Interventions: Patients were randomized 1:1 to receive doxorubicin, 75 mg/m2 (day 1), combined with olaratumab (n = 258), 20 mg/kg in cycle 1 and 15 mg/kg in subsequent cycles, or placebo (n = 251) on days 1 and 8 for up to 8 21-day cycles, followed by olaratumab/placebo monotherapy. Main Outcomes and Measures: Dual primary end points were overall survival with doxorubicin plus olaratumab vs doxorubicin plus placebo in total STS and leiomyosarcoma (LMS) populations. Results: Among the 509 patients randomized (mean age, 56.9 years; 58.2% women; 46.0% with LMS), all were included in the primary analysis and had a median length of follow-up of 31 months. No statistically significant difference in overall survival was observed between the doxorubicin plus olaratumab group vs the doxorubicin plus placebo group in either population (total STS: hazard ratio, 1.05 [95% CI, 0.84-1.30], P = .69, median overall survival, 20.4 months vs 19.7 months; LMS: hazard ratio, 0.95 [95% CI, 0.69-1.31], P = .76, median overall survival, 21.6 months vs 21.9 months). Adverse events of grade 3 or greater reported in 15% or more of total patients with STS were neutropenia (46.3% vs 49.0%), leukopenia (23.3% vs 23.7%), and febrile neutropenia (17.5% vs 16.5%). Conclusions and Relevance: In this phase 3 clinical trial of patients with advanced STS, treatment with doxorubicin plus olaratumab vs doxorubicin plus placebo resulted in no significant difference in overall survival. The findings did not confirm the overall survival benefit observed in the phase 2 trial. Trial Registration: ClinicalTrials.gov Identifier: NCT02451943.
Authors: Ian Judson; Jaap Verweij; Hans Gelderblom; Jörg T Hartmann; Patrick Schöffski; Jean-Yves Blay; J Martijn Kerst; Josef Sufliarsky; Jeremy Whelan; Peter Hohenberger; Anders Krarup-Hansen; Thierry Alcindor; Sandrine Marreaud; Saskia Litière; Catherine Hermans; Cyril Fisher; Pancras C W Hogendoorn; A Paolo dei Tos; Winette T A van der Graaf Journal: Lancet Oncol Date: 2014-03-05 Impact factor: 41.316
Authors: William D Tap; Zsuzsanna Papai; Brian A Van Tine; Steven Attia; Kristen N Ganjoo; Robin L Jones; Scott Schuetze; Damon Reed; Sant P Chawla; Richard F Riedel; Anders Krarup-Hansen; Maud Toulmonde; Isabelle Ray-Coquard; Peter Hohenberger; Giovanni Grignani; Lee D Cranmer; Scott Okuno; Mark Agulnik; William Read; Christopher W Ryan; Thierry Alcindor; Xavier F Garcia Del Muro; G Thomas Budd; Hussein Tawbi; Tillman Pearce; Stew Kroll; Denise K Reinke; Patrick Schöffski Journal: Lancet Oncol Date: 2017-06-23 Impact factor: 41.316
Authors: Timothy R Holzer; Leslie O'Neill Reising; Kelly M Credille; Andrew E Schade; Gerard J Oakley Journal: J Histochem Cytochem Date: 2016-12 Impact factor: 2.479
Authors: E A Eisenhauer; P Therasse; J Bogaerts; L H Schwartz; D Sargent; R Ford; J Dancey; S Arbuck; S Gwyther; M Mooney; L Rubinstein; L Shankar; L Dodd; R Kaplan; D Lacombe; J Verweij Journal: Eur J Cancer Date: 2009-01 Impact factor: 9.162
Authors: G Lahat; D Tuvin; C Wei; D A Anaya; B N Bekele; A J Lazar; P W Pisters; D Lev; R E Pollock Journal: Ann Surg Oncol Date: 2008-06-03 Impact factor: 5.344
Authors: William D Tap; Robin L Jones; Brian A Van Tine; Bartosz Chmielowski; Anthony D Elias; Douglas Adkins; Mark Agulnik; Matthew M Cooney; Michael B Livingston; Gregory Pennock; Meera R Hameed; Gaurav D Shah; Amy Qin; Ashwin Shahir; Damien M Cronier; Robert Ilaria; Ilaria Conti; Jan Cosaert; Gary K Schwartz Journal: Lancet Date: 2016-06-09 Impact factor: 79.321
Authors: Nicholas D Klemen; Sinchun Hwang; Martina Bradic; Evan Rosenbaum; Mark A Dickson; Mrinal M Gounder; Ciara M Kelly; Mary L Keohan; Sujana Movva; Katherine A Thornton; Ping Chi; Benjamin A Nacev; Jason E Chan; Edmund K Bartlett; Allison L Richards; Samuel Singer; Mark T A Donoghue; William D Tap; Sandra P D'Angelo Journal: Clin Cancer Res Date: 2022-03-01 Impact factor: 12.531
Authors: Brian A Van Tine; Angela C Hirbe; Peter Oppelt; Ashley E Frith; Richa Rathore; Joshua D Mitchell; Fei Wan; Shellie Berry; Michele Landeau; George A Heberton; John Gorcsan; Peter R Huntjens; Yoku Soyama; Justin M Vader; Jose A Alvarez-Cardona; Kathleen W Zhang; Daniel J Lenihan; Ronald J Krone Journal: Clin Cancer Res Date: 2021-03-25 Impact factor: 12.531
Authors: Robin L Jones; Andrew J Wagner; Akira Kawai; Kazuo Tamura; Ashwin Shahir; Brian A Van Tine; Javier Martín-Broto; Patrick M Peterson; Jennifer Wright; William D Tap Journal: Clin Cancer Res Date: 2021-02-25 Impact factor: 13.801